A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML

被引：0
|
作者：
Wei, Andrew H. [1 ]
Tan, Peter T. [2 ]
Walker, Patricia A. [2 ]
Avery, Sharon [2 ]
Patil, Sushrut S. [2 ]
Schwarer, Anthony P. [2 ]
Januszewicz, Elchanan H. [3 ]
Harrison, Simon J. [3 ]
Ho, Wai Khoon [4 ]
Tam, Constantine S. [5 ]
Spencer, Andrew
机构：
[1] Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia
[2] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Dept Haematol & Oncol, Melbourne, Australia
[4] Austin Hlth, Dept Haematol, Melbourne, Australia
[5] St Vincents Hosp, Dept Haematol, Sydney, NSW, Australia
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1548 / 1549
页数：2
相关论文
共 50 条
  • [41] The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
    Martinez-Lopez, Joaquin
    Mustjoki, Satu
    Porkka, Kimmo
    Klisovic, Rebecca B.
    Wolf, Dominik
    Busque, Lambert
    Hernandez-Boluda, Juan Carlos
    Swanink, Rene
    Martin Regueira, Patricia
    Lipton, Jeffrey H.
    LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 2040 - 2043
  • [42] Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
    Garcia, Jacqueline S.
    Wei, Andrew H.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Jurcic, Joseph G.
    Jacoby, Meagan A.
    Hong, Wan-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Tong, Bo
    Hogdal, Leah
    Kamalakar, Rajesh
    Hutti, Jessica E.
    Kye, Steve
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [43] A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
    Zeidan, Amer M.
    Pollyea, Daniel A.
    Garcia, Jacqueline S.
    Brunner, Andrew
    Roncolato, Fernando
    Borate, Uma
    Odenike, Olatoyosi
    Bajel, Ashish R.
    Watson, Anne Marie
    Gotze, Katharina
    Nolte, Florian
    Tan, Peter T.
    Hong, Wan-Jen
    Dunbar, Martin
    Zhou, Ying
    Gressick, Lori
    Ainsworth, William
    Harb, Jason
    Salem, Ahmed Hamed
    Hayslip, John
    Swords, Ronan
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [44] Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Daver, Naval G.
    Borthakur, Gautam
    Konopleva, Marina
    Ravandi, Farhad
    Wierda, William G.
    Estrov, Zeev
    Faderl, Stefan
    Kadia, Tapan
    Rey, Kristy
    Cheung, Cora
    Kantajian, Hagop M.
    BLOOD, 2011, 118 (21) : 1122 - 1122
  • [45] Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies
    Salles, Gilles A.
    Morschhauser, Franck
    Cheson, Bruce
    Rule, Simon A.
    Fegan, Christopher
    Guillaume, Cartron
    Nelson, Cara
    Yang, Yingsi
    Mitra, Siddhartha
    Starodub, Alexander
    Dyer, Martin J. S.
    BLOOD, 2016, 128 (22)
  • [46] A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients=60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
    Zeidner, Joshua F.
    Foster, Matthew C.
    Johnson, Mary
    Huang, Ying
    Swords, Ronan T.
    Stein, Eytan
    Foran, James M.
    Baer, Maria R.
    Stock, Wendy
    Madanat, Yazan F.
    Kovacsovics, Tibor
    Olin, Rebecca L.
    Blum, William G.
    Schiller, Gary J.
    Lin, Tara L.
    Redner, Robert L.
    Al-Mansour, Zeina
    Curran, Emily K.
    Heerema, Nyla A.
    Martycz, Molly
    Rosenberg, Leonard
    Marcus, Sonja
    Yocum, Ashley O.
    Chen, Timothy
    Stefanos, Mona
    Druggan, Franchesca
    Burd, Amy
    Levine, Ross L.
    Druker, Brian J.
    Borate, Uma
    Byrd, John C.
    Mims, Alice S.
    BLOOD, 2022, 140 : 9070 - 9073
  • [47] A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
    Chris Twelves
    Alan Anthoney
    Claudio I. Savulsky
    Matthew Guo
    Larisa Reyderman
    Nicola Cresti
    Vladimir Semiglazov
    Constanta Timcheva
    Ishtiaq Zubairi
    Rosemary Morrison
    Ruth Plummer
    T. R. Jeffry Evans
    British Journal of Cancer, 2019, 120 : 579 - 586
  • [48] Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
    Melani, Christopher
    Lakhotia, Rahul
    Pittaluga, Stefania
    Miljkovic, Milos D.
    Phelan, James D.
    Muppidi, Jagan R.
    Thomas, Craig J.
    Ceribelli, Michele
    Tosto, Frances Anne
    Portell, Craig A.
    Farah, Rafic J.
    Lee, Seung Tae
    Juanitez, Anna Marie
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Roschewski, Mark
    Staudt, Louis M.
    Wilson, Wyndham H.
    BLOOD, 2020, 136
  • [49] A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
    Twelves, Chris
    Anthoney, Alan
    Savulsky, Claudio, I
    Guo, Matthew
    Reyderman, Larisa
    Cresti, Nicola
    Semiglazov, Vladimir
    Timcheva, Constanta
    Zubairi, Ishtiaq
    Morrison, Rosemary
    Plummer, Ruth
    Evans, T. R. Jeffry
    BRITISH JOURNAL OF CANCER, 2019, 120 (06) : 579 - 586
  • [50] Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
    Jason D. Lickliter
    Mark Voskoboynik
    Linda Mileshkin
    Hui K. Gan
    Ganessan Kichenadasse
    Kathy Zhang
    Maggie Zhang
    Zhiyu Tang
    Michael Millward
    British Journal of Cancer, 2022, 126 : 310 - 310
12345